{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Previously Marketed
Source:
SARENIN by PROCTER AND GAMBLE
(1981)
Source URL:
First approved in 1981
Source:
SARENIN by PROCTER AND GAMBLE
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Saralasin is an angiotensin II analogue which was developed for the treatment of hypertension in 1970s. For many years saralasin was supposed to be angiotensin receptors blocker, but recent studies have revealed that its pharmacological action can be explained by agonistic behavior toward angiotensin II receptor. The drug was approved by FDA under the name Sarenin, however, it is no longer available on the market.
Status:
Possibly Marketed Outside US
Source:
NDA207947
(2015)
Source URL:
First approved in 1981
Source:
ANDA087479
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NDA207932
(1981)
Source URL:
First approved in 1981
Source:
NDA207932
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 350
(1992)
Source URL:
First approved in 1981
Source:
NDA021946
Source URL:
Class:
POLYMER
PPG-15 Stearyl Ether act as lubricants on the skin's surface, which gives the skin a soft and smooth appearance. In cosmetics and personal care products, PPG Stearyl Ethers are used mainly: in the formulation of moisturizers and cleansing products; as a solvent for organic UV filters and good carrier for essential oils and oil soluble active ingredients; to prevents crystallization of salts in antiperspirant formulations. PPG-15 Stearyl Ether was practically nonirritating to the eyes of rabbits and was slightly irritating to rabbit skin.
Status:
Possibly Marketed Outside US
Source:
NDA207932
(1981)
Source URL:
First approved in 1981
Source:
NDA207932
Source URL:
Class:
POLYMER
Status:
US Approved Rx
(1996)
First approved in 1981
Source:
BLA103676
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2012)
First approved in 1981
Class:
STRUCTURALLY DIVERSE
Status:
US Approved OTC
Source:
21 CFR 331.11(h) antacid milk solids, dried
Source URL:
First approved in 1981
Source:
BLA101833
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1981)
Source:
BLA101833
(1981)
Source URL:
First approved in 1981
Source:
BLA101833
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Allergenic Extract
(1981)
Source:
BLA101833
(1981)
Source URL:
First approved in 1981
Source:
BLA101833
Source URL:
Class:
STRUCTURALLY DIVERSE
